Drugs / Tdap
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02992418 | Dec 2016 → Dec 2019 | Dengue hemorrhagic fever | Sanofi Pasteur, a Sanofi Company | Terminated | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tdap | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02992418 ↗ |
| Modality | Vaccine | “Tdap vaccine” NCT02992418 ↗ |
| Route | Intramuscular | “0.5 mL, intramuscularly (IM) at Month 1.” NCT02992418 ↗ |